- Previous Close
5.20 - Open
5.40 - Bid 5.29 x 100
- Ask 6.72 x 200
- Day's Range
5.20 - 5.43 - 52 Week Range
0.77 - 14.30 - Volume
211,025 - Avg. Volume
246,487 - Market Cap (intraday)
171.012M - Beta (5Y Monthly) -0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-1.70 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
www.candeltx.comRecent News: CADL
View More
Performance Overview: CADL
Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CADL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CADL
View MoreValuation Measures
Market Cap
170.85M
Enterprise Value
167.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
27.77
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.31%
Return on Equity (ttm)
-480.68%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-49.99M
Diluted EPS (ttm)
-1.70
Balance Sheet and Cash Flow
Total Cash (mrq)
21.45M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-18.4M
Research Analysis: CADL
View MoreCompany Insights: CADL
CADL does not have Company Insights
Research Reports: CADL
View MoreDaily – Vickers Top Insider Picks for 03/08/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/07/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/06/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/03/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.